KEY TAKEAWAYSShares of ServiceNow are tanking 9% in premarket trading Thursday, as the software and IT services provider posted slower subscription revenue growth than it had forecast earlier and projected a slight decline in first-quarter growth.The company reported higher-than-estimated fourth-quarter adjusted earnings per share and revenue in line with estimates from analysts polled by Visible Alpha.ServiceNow shares have surged almost 50% in the past year through Wednesday. Shares of ServiceNow (NOW) ar ...

Dublin, Jan. 30, 2025 (GLOBE NEWSWIRE) -- The "A Practical Guide to Producing and Maintaining the PSMF Training Course" conference has been added to ResearchAndMarkets.com's offering. The pharmacovigilance system master file (PSMF) is a legal requirement for any medicinal product authorised in the European Union The PSMF provides the regulators with a detailed description and assessment of the entire pharmacovigilance system and the outputs contained in the annexes provide an understanding of a company's c ...

Dublin, Jan. 30, 2025 (GLOBE NEWSWIRE) -- The "Precision Poultry Nutrition Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application, Product Type" report has been added to ResearchAndMarkets.com's offering.The global Precision Poultry Nutrition market is experiencing significant growth, driven by the increasing demand for optimized poultry feed solutions to enhance productivity, improve feed efficiency, and meet rising global protein consumption. ...

Revenues of $4.4 billion (-5% as reported, -3% constant currency) Regional trends largely unchanged as Europe and North America experienced a challenging environment while Asia Pacific and Latin America saw good demand Gross profit margin of 17.2%. Staffing margins remained solid with slight decrease from mix; permanent recruitment largely stable at lower levels across most major markets SG&A reductions partially offset gross profit declines during the quarter Strong cash provided by operating activities1 ...

Dublin, Jan. 30, 2025 (GLOBE NEWSWIRE) -- The "Patentability Training Course" conference has been added to ResearchAndMarkets.com's offering. This one-day course focuses on the criteria and principles of establishing patentability of an invention through searching the literature. Patent examiners review patent applications to determine whether the claimed invention meets the established patentability criteria of novelty, non-obviousness and industrial applicability. So it's important to be prepared by perf ...

~ Independent Data Monitoring Committee Recommends Proceeding with Dose Escalation After Planned Safety Assessment of First Dose Cohort ~ ~ Company Expects to Initiate Enrollment of Second Dose Cohort in the First Quarter of 2025 ~ LEXINGTON, Mass. and AMSTERDAM, Jan. 30, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the Independent Data Monitoring Committee (IDMC) for EPISO ...

Geospatial Imagery Analytics Market Geospatial Imagery Analytics Market Dublin, Jan. 30, 2025 (GLOBE NEWSWIRE) -- The "Geospatial Imagery Analytics - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering.The global market for Geospatial Imagery Analytics is estimated at US$15.4 Billion in 2023 and is projected to reach US$102.7 Billion by 2030, growing at a CAGR of 31.1% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, ...

Dublin, Jan. 30, 2025 (GLOBE NEWSWIRE) -- The "Canada Soymilk and Soy Drinks (Dairy and Soy Food) Market Size, Growth and Forecast Analytics, 2023-2028" report has been added to ResearchAndMarkets.com's offering.The Soymilk & Soy Drinks market in Canada registered a positive compound annual growth rate (CAGR) of 1.90% during the period 2018 to 2023 with a sales value of CAD 245.50 Million in 2023, a decrease of -0.21% over 2022. The market achieved its strongest performance in 2020, when it grew by 20.56% ...

Clinical Trial Results - ATH434 demonstrated a 48% slowing of clinical progression at the 50 mg dose and 29% at the 75 mg dose on the UMSARS Part I scale at Week 52 compared to placebo [2] - The 75 mg dose showed a 62% slowing of progression at Week 26 [2] - ATH434 reduced iron accumulation in key brain regions affected by MSA, with significant results at 26 weeks for the 50 mg dose (putamen, P=0.025) and approaching significance at 52 weeks (globus pallidus, P=0.08) [3][11] - Trends in preservation of brain volume were observed in both dose groups relative to placebo at 26 and 52 weeks [3] Biomarker and Clinical Endpoints - ATH434 demonstrated reduced or stabilized iron content in key brain regions affected by MSA, as measured by MRI [8] - The 50 mg dose reduced iron accumulation in the substantia nigra, putamen, and globus pallidus, while the 75 mg dose reduced accumulation in the globus pallidus [11] - Trends of improved motor performance were observed on the Parkinson's Plus rating scale and Clinical Global Impression of Severity at the 50 mg dose (p=0.009) [2][11] - Wearable sensors showed increased activity in both dose groups, including step count, walking bouts, total walking time, and standing time [11] Safety and Tolerability - ATH434 demonstrated a favorable safety profile with no serious adverse events (SAEs) related to the treatment reported [17] - Adverse events (AEs) were mostly mild to moderate, and discontinuation rates due to AEs were similar across placebo and treatment groups [17] - The 50 mg dose group had no discontinuations due to AEs, while the 75 mg dose group had 5 discontinuations, none of which were related to treatment [17] Study Design and Population - The ATH434-201 Phase 2 trial was a randomized, double-blind, placebo-controlled study involving 77 adults with early-stage MSA across 23 sites in six countries [6] - Participants were randomized to receive either 50 mg, 75 mg of ATH434, or placebo, administered orally twice daily [6] - The modified Intent-to-Treat (mITT) population included 61 participants who received the study drug and had at least one MRI evaluation for brain iron at six months [7] Company and Drug Overview - ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration, with potential to treat Parkinson's disease and Parkinsonian disorders like MSA [13] - ATH434 has been granted Orphan Drug Designation for MSA by the U.S. FDA and the European Commission [13] - Alterity Therapeutics is a clinical-stage biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, with ATH434 as its lead candidate [15] Disease Background - Multiple System Atrophy (MSA) is a rare, rapidly progressive neurodegenerative disease with no approved treatments to slow its progression [14] - MSA affects at least 15,000 individuals in the U.S. and is characterized by autonomic nervous system failure, impaired movement, and accumulation of α-synuclein protein in the brain [14]

Visa Inc. V will release earnings results for its first quarter, after the closing bell on Thursday, Jan. 30, 2025.Analysts expect the San Francisco, California-based company to report quarterly earnings at $2.66 per share, up from $2.41 per share in the year-ago period. Visa projects to report revenue of $9.34 billion for the recent quarter, compared to $8.63 billion a year earlier, according to data from Benzinga Pro.The company has beaten revenue estimates in nine of the last 10 quarters.Visa shares gain ...